Business Wire

Armis and Security Risk Advisors Announce Strategic Partnership

2.8.2023 15:00:00 EEST | Business Wire | Press release

Share

Armis, the leading asset visibility and security company, today announced a strategic partnership with international cybersecurity consulting firm, Security Risk Advisors (SRA). This collaboration empowers joint customers as both organizations leverage their respective areas of expertise to secure operational technology (OT) and protect cyber physical systems (CPS).

As operational technology continues to become more connected, the responsibility of monitoring and securing these assets is increasingly crucial to protect business continuity, supply chain, and consumers.

“We’re extremely proud to work with such incredible global partners, including SRA,” said Tim Mackie, Vice President Worldwide Channels, Biz Dev and Alliances, Armis. “SRA’s specialized security services combined with our technology and expertise immensely benefit our shared customers. We’re happy to formalize this partnership and to work closely together to better protect critical cyber physical systems.”

Armis offers the industry’s most comprehensive asset intelligence platform providing unified asset visibility and superior security for organizations that need to protect against unseen operational and cyber risks, increase efficiencies, optimize use of resources and safely innovate with new technologies to grow.

“The most likely cause for not getting product to patients is a potential incident where a cyberattack takes a plant down and renders the computer-driven devices unusable,” said Mike Towers, Chief Security and Trust Officer, Takeda Pharmaceuticals. “We primarily deployed Armis for this use case—to improve our supply continuity and the resiliency of our overall manufacturing process. At Takeda, nothing comes before making sure that we get our medicines to patients, and Armis is one of the key contributors to making sure that we can do that.”

“Our mission is to help our clients build cybersecurity resilience in their CPS/OT ecosystem and our partnership with Armis helps with just that,” said Jason Rivera, Director, Cyber Physical Systems/OT Security, Security Risk Advisors. “This partnership with Armis enables us to better protect our clients by having a constant pulse on assets and potential risks to their environments. Their platform allows us to be more proactive about CPS/OT security measures and have a better reactive grasp on security events and incidents. We’re narrowing the gap between Armis’ industry-leading technology and organizations who need to grow their CPS/OT security capabilities.”

SRA is a member of the Armis Partner Experience (APEX) program. The mission of this program is to build long-term, strategic relationships between Armis and its partners, and to foster collaboration to serve customers in the best way possible. Apply here to become a partner.

Learn more about Armis’ OT cybersecurity solutions and how the company is helping customers secure operational technology here: https://www.armis.com/solutions/ot-device-security/

To request an ICS Risk Assessment from Armis, please visit: https://www.armis.com/ics-security-risk-assessment/

To learn more about SRA’s Cyber Physical Systems security services, please visit: https://sra.io/cpss

About Armis

Armis, the leading asset visibility and security company, provides the industry’s first unified asset intelligence platform designed to address the new extended attack surface that connected assets create. Fortune 100 companies trust our real-time and continuous protection to see with full context all managed, unmanaged assets across IT, cloud, IoT devices, medical devices (IoMT), operational technology (OT), industrial control systems (ICS), and 5G. Armis provides passive cyber asset management, risk management, and automated enforcement. Armis is a privately held company and headquartered in California.

About Security Risk Advisors

Security Risk Advisors (SRA) provides specialized security services including Penetration Testing, Purple Teams, Cloud Security, Resilience, Cyber Physical Systems Security, Engineering, and 24x7x365 Cybersecurity Operations. SRA’s mission is to “Level Up” every day to protect its clients and their customers. The company delivers security services to Fortune and Global 1000 companies, innovating technology startups, and mission-oriented non-profits. SRA is headquartered in Philadelphia, with offices in Rochester, NY and Kilkenny, Ireland.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com

Doug Webster
Marketing Manager
SRA
info@sra.io

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release

TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye